Sanofi Pasteur Inc.

Sk Bioscience Co., Ltd.

Sanofi Pasteur Sa

Boehringer Ingelheim Animal Health USA Inc.

Aventis Pasteur S.a.

Boehringer Ingelheim Vetmedica Gmbh

Philippe Talaga

Hun Rae Kim

Richard David Kensinger, Jr

Kyungjun An

Moe Kyaw

Robert Hopfer

Jinhwan Shin

Dongsoo Ham

Sunghyun Kim

Bachra Rokbi

Wooyoung Choi

Eric Desauziers

Clotilde El Guerche Seblain

Jean Haensler

Nathalie Guillo

Noëlle Mistretta

Guillaume Rigaut

Alexis Guy André Lucien Parisot

Christine Michele Pierrette Andreoni

Patricia Probeck-Quellec

Marie Garinot

Claude Meric

Véronique Chambon

Jean-François Cotte

Lydie Remolue

Karelle De Luca

Pierre-Alexandre Driguez

Sandrine Vialle-Blanc

Patricia Sepulcri

Olivier Adam

Provided are mixed carrier, multivalent pneumococcal conjugate compositions comprising 21 different pneumococcal capsular polysaccharide-protein conjugates, wherein each of the conjugates includes a capsular polysaccharide from a different serotype ofconjugated to either tetanus toxoid (TT) or CRM, wherein theserotypes are selected from 1, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11 A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F, where the capsular polysaccharides of two of serotypes 1, 3, and 5 and one or both of serotypes 15B and 22F are conjugated to TT and the remaining capsular polysaccharides are conjugated to CRM. Also provided are methods of producing the mixed carrier, multivalent pneumococcal conjugate compositions and methods of using the same for prophylaxis againstinfection or disease in a subject.

Multivalent pneumococcal polysaccharide-protein conjugate composition

The present invention provides for novel immunological and vaccine formulations comprising a newly applied non-crosslinked polyacrylic acid polymer adjuvant. The adjuvants may be combined with a wide variety of immunogens to produce vaccines that are safe and effective when administered to a wide range of target animals. The immunogens may include, but are not limited to: inactivated pathogens, attenuated pathogens, subunits, recombinant expression vectors, plasmids or combinations thereof. The animals may include, but are not limited to: humans, murine, canines, felines, equines, porcines, ovines, caprines and bovines.

Immunogenic formulations comprising linear or branched polyacrylic acid polymer adjuvants

Provided are mixed carrier, multivalent pneumococcal conjugate compositions comprising 20 different pneumococcal capsular polysaccharide-protein conjugates, wherein each of the conjugates includes a capsular polysaccharide from a different serotype ofconjugated to either tetanus toxoid or CRM, wherein theserotypes are selected from 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F, wherein two of the capsular polysaccharides are conjugated to tetanus toxoid and the remaining capsular polysaccharides are conjugated to CRMig7, and wherein the two capsular polysaccharides that are conjugated to tetanus toxoid are selected from the group consisting of serotypes 1, 3, and 5. Also provided are methods of producing the mixed carrier, multivalent pneumococcal conjugate compositions and methods of using the same for prophylaxis againstinfection or disease in a subject.

Provided are mixed carrier, multivalent pneumococcal conjugate compositions comprising 16 different pneumococcal capsular polysaccharide-protein conjugates, wherein each of the conjugates includes a capsular polysaccharide from a different serotype ofconjugated to either tetanus toxoid or CRM, wherein theserotypes are selected from 1, 3, 4, 5, 6A, 6B, 7F, 9V, 12F, 14, 18C, 19A, 19F, 22F, 23F, and 33F, wherein two of the capsular polysaccharides are conjugated to tetanus toxoid and the remaining capsular polysaccharides are conjugated to CRM, and wherein the two capsular polysaccharides that are conjugated to tetanus toxoid are selected from the group consisting of serotypes 1, 3, and 5. Also provided are methods of producing the mixed carrier, multivalent pneumococcal conjugate compositions and methods of using the same for prophylaxis againstinfection or disease in a subject.

Provided are mixed carrier, multivalent pneumococcal conjugate compositions comprising 21 different pneumococcal capsular polysaccharide-protein conjugates, wherein each of the conjugates includes a capsular polysaccharide from a different serotype ofconjugated to either tetanus toxoid (TT) or CRM, wherein theserotypes are selected from 1, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11 A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F, where the capsular polysaccharides of serotypes two of serotypes 1, 3, and 5 are conjugated to TT and the remaining capsular polysaccharides are conjugated to CRM. Also provided are methods of producing the mixed carrier, multivalent pneumococcal conjugate compositions and methods of using the same for prophylaxis againstinfection or disease in a subject.

The invention relates to a conjugate of a saccharide covalently bound to a carrier protein, wherein the saccharide comprises repetitive units of 1,5 ribitol phosphate in which all the ribitol residues are substituted by N-acetyl D-glucosaminyl residues at the 4-position, and wherein said N-acetyl D-glucosaminyl residues are exclusively in anomeric configuration &#x3b1; or are exclusively in anomeric configuration &#x3b2; and wherein the carrier protein provides at least one epitope to the conjugate which is recognized by T helper lymphocytes.

Immunogenic compositions against

The invention relates to the type 5 and type 8 capsular polysaccharides produced by overproducingstrains, and also to the immunogenic compositions and the vaccines comprising said capsular polysaccharides.

[object Object]

The invention relates to a method for assaying the teichoic acids present, most commonly in residual form, in a preparation of Gram+ bacterial antigens. This method requires, first of all, a controlled hydrolysis with hydrofluoric acid at a temperature of less than or equal to 40&#xb0; C., in order to release the oligosaccharides specific for teichoic acids. The assaying of the specific oligosaccharides can then be carried out by various techniques, in particular by high performance chromatography coupled with pulsed amperometric detection (HPAEC-PAD). The method according to the invention can in particular be used to assay the residual amounts of teichoic acids present in preparations containing capsular polysaccharides ofwhich may be useful as vaccines.

Growing community of inventors

Lyons, France

Philippe Talaga